These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11036115)

  • 1. Mutational analysis of endothelial cells derived from von Hippel-Lindau-related renal cancer.
    Los M; Kerckhaert OA; Zewald R; van Amstel HK; Voest EE
    J Natl Cancer Inst; 2000 Oct; 92(20):1688-9. PubMed ID: 11036115
    [No Abstract]   [Full Text] [Related]  

  • 2. Von Hippel-Lindau (VHL) gene analysis in Italian families with VHL disease.
    Montera M; Bellone E; Ajmar F; Mandich P
    Contrib Nephrol; 1997; 122():109-11. PubMed ID: 9399050
    [No Abstract]   [Full Text] [Related]  

  • 3. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
    Decker HJ; Weidt EJ; Brieger J
    Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
    Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
    Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer.
    Shuin T; Kondo K; Ashida S; Okuda H; Yoshida M; Kanno H; Yao M
    Contrib Nephrol; 1999; 128():1-10. PubMed ID: 10597373
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current progress in the diagnosis and treatment of renal cell carcinoma].
    Tsukamoto T; Takahashi A; Kitamura H
    Nihon Jinzo Gakkai Shi; 2002 Dec; 44(8):779-85. PubMed ID: 12607966
    [No Abstract]   [Full Text] [Related]  

  • 7. Closing in on another renal cancer suppressor locus near chromosome 3p14.
    Kaye FJ
    J Natl Cancer Inst; 1999 Sep; 91(18):1528-9. PubMed ID: 10491421
    [No Abstract]   [Full Text] [Related]  

  • 8. Von Hippel-Lindau disease: the role of gene analysis in affected families.
    Riegler P; Huber W; Corradini R; Neumann HP; Glaesker S; Sessa A
    Nephron; 2000 Jan; 84(1):95-7. PubMed ID: 10644921
    [No Abstract]   [Full Text] [Related]  

  • 9. [Genetic backgrounds of renal cell carcinoma].
    Oya M
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():593-6. PubMed ID: 16523961
    [No Abstract]   [Full Text] [Related]  

  • 10. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
    Richard S
    Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development.
    van den Berg A; Dijkhuizen T; Draaijers TG; Hulsbeek MM; Maher ER; van den Berg E; Störkel S; Buys CH
    Genes Chromosomes Cancer; 1997 Aug; 19(4):228-32. PubMed ID: 9258657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.
    Linehan WM; Lerman MI; Zbar B
    JAMA; 1995 Feb; 273(7):564-70. PubMed ID: 7837390
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningioma showing VHL gene inactivation in a patient with von Hippel-Lindau disease.
    Kanno H; Yamamoto I; Yoshida M; Kitamura H
    Neurology; 2003 Apr; 60(7):1197-9. PubMed ID: 12682336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of biallelic inactivation of the von Hippel-Lindau tumor suppressor gene VHL in patients of renal cell carcinoma patient].
    Liu N; Gong K; Zhang N; Guo HF; Na X; Wu G; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(2):115-7. PubMed ID: 15771820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Hippel-Lindau disease: how does one gene cause multiple tumors?
    Roach ES
    Neurology; 1999 Jul; 53(1):7-8. PubMed ID: 10408528
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1).
    Meléndez B; Rodríguez-Perales S; Martínez-Delgado B; Otero I; Robledo M; Martínez-Ramírez A; Ruiz-Llorente S; Urioste M; Cigudosa JC; Benítez J
    Hum Genet; 2003 Feb; 112(2):178-85. PubMed ID: 12522559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A.
    Chen F; Slife L; Kishida T; Mulvihill J; Tisherman SE; Zbar B
    J Med Genet; 1996 Aug; 33(8):716-7. PubMed ID: 8863170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.